NewsSTAT
Ranked by formulaVerdict: RoutineSTAT+: A possible comeback for a failed sickle cell gene therapy
Three years ago, a trial for a sickle cell gene-editing therapy a decade in the making ended abruptly after the first patient suffered a serious adverse event.
Score████░░░░░░3.8
Caveats
- Not randomized: its findings are associations.
VerdictCompetent work. Briefs at most.
Summary from the source
Three years ago, a trial for a sickle cell gene-editing therapy a decade in the making ended abruptly after the first patient suffered a serious adverse event. Now, the therapy…
The editor's rubric
- Leverage2 / 5
- Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt).
- Magnitude2 / 5
- Solid incremental gain on a meaningful problem.
- Evidence2 / 5
- Limited: single setting, weak baselines, or an observational association presented as causal.
- Novelty2 / 5
- A new combination of known ideas.
- Trajectory2 / 5
- Some room to improve with obvious engineering.
- Stakes3 / 5
- Meaningful benefit to many people within a few years.
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: verification (error bars); stakes (major disease, prevention or cure). Red flags: not randomized.
How the score was computed
Score████░░░░░░3.8
Desks place stronger verdicts first, then use this score to order work within the same verdict.
- Merit
- 3.8 / 10
- Adjusted merit
- 3.9 / 10
- Attention
- 28%
- Freshness
- 45%